Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02282735 · ClinicalTrials.gov registry record
Parental Decision-Making for Children With Relapsed Neuroblastoma
A clinical trial of Relapsed Neuroblastoma, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- 96
- Enrollment target
- 9
- Study locations
NCT02282735 is a study of Relapsed Neuroblastoma that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 96 participants, above the 44-participant average among 8 other Relapsed Neuroblastoma trials with a reported enrollment target (118% higher). The trial reports 9 study locations across 8 states.
The verdict
NCT02282735, a study of Relapsed Neuroblastoma, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 96 participants
- Enrollment target
- 9
- Study locations
Study Summary
Parental decision-making for children with advanced cancer is complex. Many parents have overly optimistic beliefs about prognosis and as a result choose aggressive measures even at the end of life, which are associated with greater suffering. Yet most parents wish to limit suffering, and in retrospect, many regret choices for cancer treatment for advanced cancer. These findings suggest that parents do not always have the information they need to make decisions that reflect their preferences. The proposed study will evaluate parental decision-making in advanced cancer, addressing gaps in the literature in 3 important respects. 1) Previous work on decision-making for children with advanced cancer has typically looked at decisions at one point in time, often asking parents to reflect on decisions after the child's death, even though parents' understanding of prognosis and decisions about care evolve over time. We will evaluate parental decision-making for advanced cancer over time. 2) Existing work focuses on aggressive end-of-life care as the worst possible outcome. However, some parents wish to pursue aggressive measures even when they recognize that the child has little chance for cure. We will evaluate the extent to which parental decision-making is informed and consonant with preferences, regardless of whether decisions lead to aggressive or palliative care. 3) Previous studies have focused on groups of different childhood cancers, making it difficult to ascertain whether differences in decision-making reflect differences in diseases, options for care, or parent preferences. We will focus on a single disease, relapsed neuroblastoma, as a model for parental decision-making.
Conditions Studied
Study Locations (9)
California
- Children's Hospital of Los Angeles - Los Angeles
- Stanford/Packard's Children's Hospital - Palo Alto
Illinois
- The University of Chicago Medical Center - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Columbia University Medical Center - New York
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- Cook's Children's Healthcare System - Fort Worth
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2013-05 |
| Est. Completion | 2027-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02282735
The ClinicalTrials.gov registry entry for NCT02282735 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 44-participant average among 8 other Relapsed Neuroblastoma trials with a reported enrollment target (118% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed Neuroblastoma appearing as the primary indexed condition, and to 0 interventions.
NCT02282735 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02282735 about?
NCT02282735 is a clinical study titled "Parental Decision-Making for Children With Relapsed Neuroblastoma". Parental decision-making for children with advanced cancer is complex. Many parents have overly optimistic beliefs about prognosis and as a result choose aggressive measures even at the end of life, which are associated with greater suffering. Yet most parents wish to limit suffering, and in retrosp...
What is the current status of trial NCT02282735?
This trial is currently active not recruiting. The enrollment target is 96 participants. The study started on 2013-05. Estimated completion is 2027-06.
What conditions does trial NCT02282735 study?
This clinical trial studies the following conditions: Relapsed Neuroblastoma.
Who is sponsoring clinical trial NCT02282735?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02282735 being conducted?
This trial has 9 study locations across California, Illinois, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
RECRUITING · Phase 1
-
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
RECRUITING · Phase 1
-
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
RECRUITING · Phase 1
-
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
RECRUITING · Phase 1
-
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RECRUITING · Phase 1
-
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.